← Back to Clinical Trials
Recruiting NCT04049279

Migration in Total Hip Arthroplasty with a Cemented BiMobile Cup: Better Stability with More Cement?

Trial Parameters

Condition Total Hip Arthroplasty
Sponsor JointResearch
Study Type INTERVENTIONAL
Phase N/A
Enrollment 75
Sex ALL
Min Age 65 Years
Max Age N/A
Start Date 2019-01-01
Completion 2026-05-01
Interventions
BiMobile standard cementBiMobile larger cementAvantage standard cement

Brief Summary

Objective: The main objective of this study is to compare the (early) migration of the cemented BiMobile cup at two year post-surgery between two different cup sizes after standard optimal reaming, and consequently adjusting the cement mantle into circa 2 or 4 mm, in patients with a primary cemented total hip arthroplasty (THA). Additionally, the results of the BiMobile cup will be compared to the Avantage cup, which is placed with a standard cup size, resulting in a cement mantle of approximately 2 mm. Study design: A prospective single centre blinded randomised controlled trial. Study population: All patients who meet the criteria to undergo a cemented THA.

Eligibility Criteria

Inclusion Criteria: * Patient requiring an elective primary cemented THA. * Male patient ≥70 years old and female patient ≥65 years old. * Ability and willingness to follow instructions and to return for follow-up evaluations. * The patient is able to understand the meaning of the study and is willing to sign informed consent. * Understanding the Dutch language. Exclusion Criteria: * The patient is morbidly obese, defined as Body Mass Index (BMI) of ≥ 40. * The patient is expected to need lower limb joint replacement for another joint within one year. * The patient has a systemic or metabolic disorder leading to progressive bone deterioration. * The patient has a deformity or disease located in other joints than the hip that needs surgery and that is limiting their ability to walk. * The patient has an active or suspected latent infection in or around the hip joint. * The patient's bone stock is compromised by a disease or infection which cannot provide adequate support and/or fixation

Related Trials